NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization42.71 mln
Float5.58 mln
Earnings Date12/11/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
16
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-118
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Edesa Biotech is a Canadian biopharmaceutical company focused on developing treatments for inflammatory and immune-related conditions, with a pipeline that includes both injectable antibody therapies and topical creams. Its most advanced programs target serious conditions such as acute respiratory distress syndrome, chronic skin allergies, and pulmonary fibrosis, with several candidates already in late-stage clinical trials. The company works alongside research partners in Switzerland and Israel to broaden the reach of its drug development efforts across human and animal health applications. Founded in 2015 and based in Markham, Ontario, Edesa continues to advance its portfolio from early research through to potential commercialization.